Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.8% Higher - Should You Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) traded up 0.8% during trading on Monday . The company traded as high as $6.07 and last traded at $5.78. 5,183,271 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 12,256,373 shares. The stock had previously closed at $5.73.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on RXRX shares. Morgan Stanley cut their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $8.20.

Recursion Pharmaceuticals Trading Up 2.4 %

The stock has a market capitalization of $2.36 billion, a PE ratio of -3.83 and a beta of 1.00. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a 50 day moving average price of $6.21 and a 200-day moving average price of $6.78.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. During the same quarter last year, the firm posted ($0.42) earnings per share. The business's quarterly revenue was down 57.8% compared to the same quarter last year. Sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $26,000. Private Trust Co. NA bought a new position in Recursion Pharmaceuticals during the fourth quarter valued at approximately $27,000. GAMMA Investing LLC increased its stake in Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after acquiring an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after acquiring an additional 1,353 shares during the last quarter. Finally, NewEdge Advisors LLC grew its holdings in shares of Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after purchasing an additional 2,387 shares in the last quarter. 89.06% of the stock is owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.